Novavax, Inc. (NVAX)
| Previous Close | 188.57 |
| Open | 206.17 |
| Bid | 220.00 x 800 |
| Ask | 221.13 x 1100 |
| Day's Range | 202.59 - 228.00 |
| 52 Week Range | 76.59 - 331.68 |
| Volume | 5,915,556 |
| Avg. Volume | 4,069,893 |
| Market Cap | 16.244B |
| Beta (5Y Monthly) | 1.60 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -9.51 |
| Earnings Date | Aug. 05, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 271.75 |
- Editor's PickYahoo Finance Video
Chef Eric Ripert on requiring proof of vaccinations: ‘It’s not an easy decision to take’
Eric Ripert, Chef & Co-Owner of Le Bernardin, joins Yahoo Finance Live to discuss Le Bernardin’s requirement of proof of vaccination to dine indoors, the labor shortage, and outlook for the restaurant industry amid the rise in Covid-19 cases.
- Editor's PickYahoo Finance Video
Covid vaccine needs to be distributed exactly how the flu vaccine’s distributed: Henry Schein CEO
Stan Bergman, Henry Schein CEO, speaks with Yahoo Finance on submitting a letter to the Congressional subcommittee supporting expanded COVID-19 vaccine distribution.
- Reuters
UPDATE 2-EU seals deal with Novavax for up to 200 million COVID-19 vaccines
The European Commission has approved a supply contract with U.S. firm Novavax to buy up to 200 million doses of its potential COVID-19 vaccine, the Commission said on Wednesday. "Our new agreement with Novavax expands our vaccine portfolio to include one more protein-based vaccine, a platform showing promise in clinical trials," EU health commissioner Stella Kyriakides said in a statement. French drugmaker Sanofi, in partnership with British firm GlaxoSmithKline, is also trying to produce a protein-based COVID-19 vaccine and has already signed a supply deal with the EU.
